Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Other Investing Activities

Investing cash flows not reported separately.

Scilex Holding CompanyNASDAQ: SCLX

Other Investing Activities · Q1 FY2026 · quarter ended Mar 2026

Other investing activities grows, but more slowly than its trailing trend

Q1 FY2026 other investing activities of $12.11M (cash outflow) rose 5952.5% year over year, behind the +6109.8% change in trailing-twelve-month other investing activities. Sequentially, it rose 48878.4% from the prior quarter.

Context

  • Other investing activities amounted to 13.9% of revenue in FY2025, up 13.9 pp from a year earlier.
  • Other investing activities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5952.5% toward the trailing-twelve-month pace of +6109.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.11M+48878.4% QoQ
Last fiscal yearDec 2025
$4.22M— YoY
LTMMar 2026
-$20.5M+6109.8% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5952.5%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

USD · from the cash flow

Latest · FY2025
4.22M USD
Year-over-year change
—

Other Investing Activities vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 other investing activities of $20.5M is the largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of +6109.8% is the highest of 6, against a peer median of -79.3%.
  • Other investing activities amounts to 60.6% of revenue for SCLX, versus a peer median of 0.1%.
SCLX Competitors Peer median
Other Investing Activities for SCLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SCLXScilex Holding CompanyLTM Mar 2026$20.5M +6109.8%—60.6%
CTORCitius Oncology, Inc.LTM Mar 2026$10.86M +117.1%—193.4%
AGENAgenus Inc.LTM Mar 2026$359K +1395.8%-89.7%0.3%
SEERSeer, Inc.LTM Mar 2026$133K -79.3%—0.9%
IRDOpus Genetics, Inc.LTM Mar 2026$0 -100.0%—0.0%
ALECAlector, Inc.LTM Mar 2026$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 ———
LUCDLucid Diagnostics Inc.LTM Mar 2026$0 ——0.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 -100.0%——
Peer median (excluding SCLX) $0-79.3%-89.7%0.1%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Depreciation & Amortization3.78M3.96M4.15M4.05M4.62M
Deferred Income Tax12.76M0000
Stock-Based Compensation5.82M5.28M14.6M15.69M15.49M
Change in Working Capital13.6M45.67M65.8M64.84M113.97M
Accounts Receivables(1.14M)(6.97M)(13.36M)(6.27M)13.84M
Inventory(1.42M)1.18M(2.84M)1.46M1.8M
Accounts Payables(3.84M)2.81M19.88M7.42M13.12M
Other Working Capital20M48.65M62.12M62.23M85.21M
Other Non-Cash Items23.79M(52.8M)9.08M7.58M228.47M
Operating Cash Flow(28.66M)(21.26M)(20.71M)19.35M3.82M
Capital Expenditures0(2.07M)(330K)(600K)(133K)
Acquisitions (Net)00000
Purchases of Investments000(2.08M)0
Sales of Investments00000
Other Investing Activities00(300K)04.22M
Investing Cash Flow0(2.07M)(330K)(2.68M)4.08M
Debt Repayment(19.69M)(31.25M)728K(64.21M)(2.81M)
Common Stock Issued096K35.46M44.64M27.88M
Common Stock Repurchased00(10M)00
Dividends Paid00000
Other Financing Activities47.85M52.33M(2.6M)1.44M(30.53M)
Financing Cash Flow28.16M21.17M23.58M(18.13M)(5.46M)
Effect of Forex Changes0000(756K)
Net Change in Cash(501K)(2.15M)2.55M(1.46M)1.68M
Free Cash Flow(28.66M)(23.33M)(21.04M)18.75M3.68M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.